Filing Details

Accession Number:
0001104659-20-106111
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-09-17 16:15:24
Reporting Period:
2020-09-15
Accepted Time:
2020-09-17 16:15:24
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1722964 Y-Mabs Therapeutics Inc. YMAB Pharmaceutical Preparations (2834) 474619612
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1753224 Thomas Gad C/O Y-Mabs Therapeutics, Inc.
230 Park Avenue, Suite 3350
New York NY 10169
President And Chairman Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2020-09-15 4,000 $40.81 642,000 No 4 S Indirect By GAD Enterprises LLC
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect By GAD Enterprises LLC
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 1,030,356 Indirect By WG Biotech ApS
Footnotes
  1. Represents shares sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 30, 2020.
  2. This transaction was executed in multiple trades at prices ranging from $41.95 to $39.11. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
  3. Reporting Person is sole member of GAD Enterprises, LLC and the sole member and manager of GAD Management, LLC, the manager of GAD Enterprises, LLC, and as such Reporting Person has sole voting and dispositive power with respect to such shares.
  4. WG Biotech ApS owns 5,508,392 shares of the Issuer's common stock. GAD Enterprises, LLC (of which Reporting Person is sole member) owns approximately 18.71% of WG Biotech ApS but has no voting or dispositive power over the shares of common stock held by WG Biotech ApS.